TuHURA BIOSCIENCES, INC./NV Pre-Tax Income
TuHURA BIOSCIENCES, INC./NV (HURA) reported Pre-Tax Income of -$30.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-03-31
- TuHURA BIOSCIENCES, INC./NV income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$30.05M.
- TuHURA BIOSCIENCES, INC./NV income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$21.68M, a 174.00% decline from fiscal 2023.
- TuHURA BIOSCIENCES, INC./NV income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was $29.30M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$30.05M 10-K · filed 2026-03-31 | |
| 2024-12-31 | -$21.68M 10-K · filed 2026-03-31 | $21.70M 10-K · filed 2025-03-31 |
| 2023-12-31 | $29.30M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |